PCVX Vaxcyte, Inc. Stock Quote

PCVX [NASD]

Index	-	P/E	-	EPS (ttm)	-2.19	Insider Own	1.50%	Shs Outstand	57.55M	Perf Week	2.36%
Market Cap	1.30B	Forward P/E	-	EPS next Y	-2.81	Insider Trans	-12.53%	Shs Float	50.28M	Perf Month	-19.41%
Income	-117.80M	PEG	-	EPS next Q	-0.69	Inst Own	89.20%	Short Float	4.03%	Perf Quarter	-11.54%
Sales	-	P/S	-	EPS this Y	36.20%	Inst Trans	10.22%	Short Ratio	5.25	Perf Half Y	-9.74%
Book/sh	6.25	P/B	3.33	EPS next Y	-3.60%	ROA	-32.80%	Target Price	48.50	Perf Year	-13.17%
Cash/sh	5.35	P/C	3.89	EPS next 5Y	4.70%	ROE	-37.20%	52W Range	16.78 - 27.44	Perf YTD	-12.40%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-24.05%	Beta	-
Dividend %	-	Quick Ratio	12.60	Sales past 5Y	-	Gross Margin	-	52W Low	24.20%	ATR	1.47
Employees	89	Current Ratio	12.60	Sales Q/Q	-	Oper. Margin	-	RSI (14)	48.29	Volatility	6.63% 7.63%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-63.40%	Profit Margin	-	Rel Volume	0.98	Prev Close	20.52
Shortable	Yes	LT Debt/Eq	0.00	Earnings	May 09 AMC	Payout	-	Avg Volume	386.05K	Price	20.84
Recom	1.50	SMA20	1.58%	SMA50	-8.81%	SMA200	-9.45%	Volume	378,712	Change	1.56%

Dec-29-21

Resumed

Jefferies

Buy

$50

Jun-24-21

Resumed

Jefferies

Buy

$50

Jul-07-20

Initiated

Needham

Buy

$40

Jul-07-20

Initiated

Cantor Fitzgerald

Overweight

$55

Jul-07-20

Initiated

BofA Securities

Buy

$37

Jun-27-22 07:30PM	Astellas and Sutro Biopharma Announce Worldwide Strategic Collaboration to Advance Novel Immunostimulatory Antibody-Drug Conjugates (iADCs) PR Newswire +5.23%
Jun-02-22 04:05PM	Vaxcyte to Present at the Jefferies Healthcare Conference GlobeNewswire
May-09-22 04:10PM	Vaxcyte Reports First Quarter 2022 Financial Results and Provides Business Update GlobeNewswire -11.78%
May-04-22 01:34PM	Could The Vaxcyte, Inc. (NASDAQ:PCVX) Ownership Structure Tell Us Something Useful? Simply Wall St.
May-03-22 08:30AM	Vaxcyte to Participate in Upcoming Investor Conferences in May GlobeNewswire
Apr-05-22 08:30AM	Vaxcyte to Present at the 21st Annual Needham Virtual Healthcare Conference GlobeNewswire
Apr-04-22 08:30AM	Vaxcyte Doses First Participants in Phase 2 Portion of Ongoing VAX-24 Phase 1/2 Clinical Proof-of-Concept Study in Adults GlobeNewswire +7.10%
Mar-08-22 04:59AM	Companies Like Vaxcyte (NASDAQ:PCVX) Are In A Position To Invest In Growth Simply Wall St.
Feb-28-22 04:10PM	Vaxcyte Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update GlobeNewswire
Feb-23-22 04:05PM	Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults GlobeNewswire
Feb-17-22 08:30AM	Vaxcyte to Report Fourth Quarter and Full Year 2021 Financial Results on February 28, 2022 GlobeNewswire
Feb-10-22 08:30AM	Vaxcyte to Present at the 11th Annual SVB Leerink Global Healthcare Conference GlobeNewswire
Jan-31-22 07:00AM	Athira Pharma Announces Appointment of Grant Pickering to its Board of Directors GlobeNewswire +6.79%
Jan-13-22 07:09AM	Vaxcyte Raises $100M Via Equity To Fund Development Of Lead Pneumococcal Vaccine Candidate Benzinga -9.50%
01:07AM	Vaxcyte Announces Pricing of $100 Million Public Offering GlobeNewswire
Jan-12-22 04:10PM	Vaxcyte Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants GlobeNewswire -6.82%
Jan-06-22 08:30AM	Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-24 for the Prevention of Invasive Pneumococcal Disease GlobeNewswire
Dec-31-21 10:00AM	Wall Street Analysts Think Vaxcyte, Inc. (PCVX) Could Surge 96%: Read This Before Placing a Bet Zacks -6.52%
Nov-15-21 10:23AM	Does Vaxcyte (PCVX) Have the Potential to Rally 89% as Wall Street Analysts Expect? Zacks
Nov-11-21 04:05PM	Vaxcyte to Present at Upcoming Investor Conferences GlobeNewswire
Nov-10-21 04:10PM	Vaxcyte Reports Third Quarter 2021 Financial Results and Provides Business Update GlobeNewswire
Oct-28-21 08:30AM	Vaxcyte Appoints Carlos Paya and Michael Kamarck to Its Board of Directors GlobeNewswire +5.72%
Oct-04-21 10:04AM	Hedge Fund Sentiment Is Stagnant On Vaxcyte, Inc. (PCVX) Insider Monkey
Sep-30-21 11:17AM	Notable Vaxcyte Insider Trades $130K In Company Stock Benzinga
Sep-28-21 04:05PM	Vaxcyte to Present at Guggenheim 2nd Annual Vaccine and Infectious Disease Conference GlobeNewswire
Sep-21-21 04:01PM	Vaxcyte to Present at 2021 Cantor Virtual Global Healthcare Conference GlobeNewswire
Sep-20-21 04:30PM	Vaxcyte Appoints Annie Drapeau and Teri Loxam to Its Board of Directors GlobeNewswire
Sep-13-21 10:35AM	Vaxcyte (NASDAQ:PCVX) Is In A Good Position To Deliver On Growth Plans Simply Wall St.
Aug-11-21 04:07PM	Vaxcyte Reports Second Quarter 2021 Financial Results and Provides Business Update GlobeNewswire
Aug-05-21 08:30AM	Vaxcyte Announces Expanded CARB-X Award to Advance Development of VAX-A1, a Vaccine to Prevent Group A Streptococcus Infections GlobeNewswire
Aug-03-21 09:01AM	10 Stocks to Buy According to Neil Shahrestanis Ikarian Capital Insider Monkey
May-27-21 04:05PM	Vaxcyte to Present at the Jefferies Virtual Healthcare Conference GlobeNewswire
May-11-21 04:10PM	Vaxcyte Reports First Quarter 2021 Financial Results and Provides Business Update GlobeNewswire +5.41%
May-10-21 08:30AM	Vaxcyte Announces Publication of Preclinical Data Supporting the Potential of VAX-24 for the Prevention of Invasive Pneumococcal Disease GlobeNewswire -6.75%
May-06-21 04:05PM	Vaxcyte to Present at BofA Securities 2021 Health Care Conference GlobeNewswire
Apr-05-21 04:30PM	Vaxcyte to Present at 20th Annual Needham Virtual Healthcare Conference GlobeNewswire +6.26%
Mar-29-21 04:10PM	Vaxcyte Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update GlobeNewswire
02:30PM	Vaxcyte Inc to Host Earnings Call ACCESSWIRE
Mar-25-21 07:11AM	UPDATE 3-Former U.S. govt vaccine chief exits two drug developers after GSK harassment claim Reuters +11.40%
06:48AM	Former U.S. govt vaccine chief exits two drug developers after GSK harassment claim Reuters
Mar-22-21 04:05PM	Vaxcyte to Report Fourth Quarter and Full Year 2020 Financial Results on March 29, 2021 GlobeNewswire -6.69%
Mar-15-21 06:34AM	We Think Vaxcyte (NASDAQ:PCVX) Can Easily Afford To Drive Business Growth Simply Wall St.
Jan-06-21 08:15AM	Vaxcyte Announces Publication of Preclinical Proof-of-Concept Data Supporting Potential of VAX-A1, a Novel Conjugate Vaccine Designed to Prevent Group A Strep Infections GlobeNewswire +6.58%
Dec-22-20 08:00AM	Vaxcyte Promotes Andrew Guggenhime to President and Chief Financial Officer GlobeNewswire
Dec-10-20 06:34PM	Is PCVX A Good Stock To Buy Now? Insider Monkey
Nov-24-20 04:05PM	Vaxcyte to Present at Evercore ISI 3rd Annual HealthCONx Conference GlobeNewswire
Nov-12-20 04:15PM	Vaxcyte Reports Third Quarter 2020 Financial Results and Provides Business Update GlobeNewswire
Nov-10-20 04:41PM	Vaxcyte to Present at Jefferies Virtual London Healthcare Conference GlobeNewswire
Sep-23-20 07:00AM	Longitude Capital Raises $585 Million Fund to Invest in Transformative Healthcare Companies GlobeNewswire
Sep-14-20 02:27PM	We're Interested To See How Vaxcyte (NASDAQ:PCVX) Uses Its Cash Hoard To Grow Simply Wall St.
Sep-09-20 05:28PM	Vaxcyte to Present at 2020 Cantor Virtual Global Healthcare Conference GlobeNewswire
Aug-14-20 03:01PM	Dow Jones Edges Higher In New Bid For 28,000; Tesla, AMAT Stock Lead Nasdaq Investor's Business Daily +8.71%
Aug-12-20 04:59PM	CORRECTION Vaxcyte Reports Second Quarter 2020 Financial Results and Provides Business Update GlobeNewswire +8.00%
04:10PM	Vaxcyte Reports Second Quarter 2020 Financial Results and Provides Business Update GlobeNewswire
Jun-16-20 04:05PM	Vaxcyte Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire +15.36%
Jun-12-20 11:24AM	Vaccine maker Vaxcyte's shares soar 22% in trading debut MarketWatch
06:18AM	Vaccine maker Vaxcyte upsizes IPO and prices at top end of range MarketWatch
01:06AM	Vaxcyte Announces Pricing of Upsized Initial Public Offering GlobeNewswire
Jun-03-20 08:30AM	Vaxcyte Appoints Halley E. Gilbert to Board of Directors GlobeNewswire
May-21-20 08:30AM	SutroVax Announces Name Change to Vaxcyte GlobeNewswire

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
PICKERING GRANT	Chief Executive Officer	Jun 28	Sale	21.00	10,000	210,000	345,660	Jun 28 05:14 PM
PICKERING GRANT	Chief Executive Officer	Jun 24	Sale	21.01	747	15,696	694,456	Jun 28 05:14 PM
PICKERING GRANT	Chief Executive Officer	Jun 23	Sale	21.01	3,541	74,410	695,203	Jun 23 05:48 PM
PICKERING GRANT	Chief Executive Officer	Jun 22	Sale	21.01	1,261	26,492	698,744	Jun 23 05:48 PM
PICKERING GRANT	Chief Executive Officer	Jun 21	Sale	21.05	5,451	114,736	700,005	Jun 23 05:48 PM
Sauer Paul	SVP Process Dev, Manufacturing	May 23	Sale	26.22	3,000	78,670	23,687	May 25 04:24 PM
Fairman Jeff	VP, Research	May 20	Sale	25.50	4,112	104,856	321,227	May 24 04:32 PM
GUGGENHIME ANDREW	President and CFO	May 18	Option Exercise	5.35	3,100	16,585	45,287	May 20 05:01 PM
GUGGENHIME ANDREW	President and CFO	May 18	Sale	24.44	3,100	75,763	42,187	May 20 05:01 PM
PICKERING GRANT	Chief Executive Officer	May 16	Option Exercise	1.79	11,000	19,690	714,894	May 18 04:39 PM
PICKERING GRANT	Chief Executive Officer	May 16	Sale	23.91	11,000	262,990	703,894	May 18 04:39 PM
Fairman Jeff	VP, Research	May 05	Sale	25.80	888	22,914	325,339	May 09 04:35 PM
Sauer Paul	SVP Process Dev, Manufacturing	Apr 22	Sale	25.00	3,000	75,000	25,125	Apr 26 05:18 PM
Wassil Jim	Chief Operating Officer	Apr 18	Option Exercise	2.42	2,800	6,776	45,744	Apr 20 04:56 PM
PICKERING GRANT	Chief Executive Officer	Apr 18	Option Exercise	1.79	11,000	19,690	714,894	Apr 20 04:54 PM
GUGGENHIME ANDREW	President and CFO	Apr 18	Option Exercise	5.35	3,100	16,585	43,725	Apr 20 04:55 PM
PICKERING GRANT	Chief Executive Officer	Apr 18	Sale	23.98	11,000	263,766	703,894	Apr 20 04:54 PM
GUGGENHIME ANDREW	President and CFO	Apr 18	Sale	24.05	3,100	74,542	40,625	Apr 20 04:55 PM
Wassil Jim	Chief Operating Officer	Apr 18	Sale	23.98	2,800	67,130	42,944	Apr 20 04:56 PM
Fairman Jeff	VP, Research	Apr 05	Sale	25.59	5,000	127,950	326,227	Apr 07 05:24 PM
PICKERING GRANT	Chief Executive Officer	Mar 22	Option Exercise	1.79	7,712	13,804	711,606	Mar 23 06:03 PM
PICKERING GRANT	Chief Executive Officer	Mar 22	Sale	24.62	7,712	189,862	703,894	Mar 23 06:03 PM
Sauer Paul	SVP Process Dev, Manufacturing	Mar 22	Sale	25.00	3,000	75,000	28,125	Mar 24 06:05 PM
PICKERING GRANT	Chief Executive Officer	Mar 21	Option Exercise	1.79	14,288	25,576	718,182	Mar 23 06:03 PM
PICKERING GRANT	Chief Executive Officer	Mar 21	Sale	24.94	14,288	356,281	703,894	Mar 23 06:03 PM
GUGGENHIME ANDREW	President and CFO	Mar 18	Option Exercise	5.35	3,100	16,585	43,725	Mar 22 04:22 PM
GUGGENHIME ANDREW	President and CFO	Mar 18	Sale	26.13	3,100	80,993	40,625	Mar 22 04:22 PM
Fairman Jeff	VP, Research	Mar 11	Sale	25.50	10,000	255,000	331,227	Mar 15 09:09 PM
Sauer Paul	SVP Process Dev, Manufacturing	Mar 10	Sale	25.00	6,000	150,000	31,125	Mar 14 05:03 PM
GUGGENHIME ANDREW	President and CFO	Mar 01	Option Exercise	5.35	6,200	33,170	9,325	Mar 03 04:39 PM
GUGGENHIME ANDREW	President and CFO	Mar 01	Sale	24.00	6,200	148,800	3,125	Mar 03 04:39 PM
Wassil Jim	Chief Operating Officer	Feb 24	Option Exercise	2.42	10,000	24,200	27,944	Feb 28 05:17 PM
Wassil Jim	Chief Operating Officer	Feb 24	Sale	22.00	10,000	220,000	17,944	Feb 28 05:17 PM
Sauer Paul	SVP Process Dev, Manufacturing	Dec 29	Sale	25.00	6,000	150,000	27,125	Dec 30 04:36 PM
Fairman Jeff	VP, Research	Dec 27	Option Exercise	1.79	4,750	8,502	10,910	Dec 28 04:15 PM
PICKERING GRANT	Chief Executive Officer	Dec 27	Option Exercise	1.80	51,765	92,995	632,019	Dec 28 04:14 PM
Fairman Jeff	VP, Research	Dec 27	Sale	23.60	4,750	112,092	6,160	Dec 28 04:15 PM
GUGGENHIME ANDREW	President and CFO	Dec 23	Option Exercise	5.35	3,100	16,585	6,225	Dec 28 04:13 PM
GUGGENHIME ANDREW	President and CFO	Dec 23	Sale	24.00	3,100	74,400	3,125	Dec 28 04:13 PM
Fairman Jeff	VP, Research	Dec 20	Option Exercise	1.79	4,469	8,000	10,629	Feb 08 05:27 PM
Fairman Jeff	VP, Research	Dec 16	Option Exercise	1.79	4,619	8,268	10,779	Dec 20 04:35 PM
Fairman Jeff	VP, Research	Dec 16	Sale	22.50	4,619	103,928	6,160	Dec 20 04:35 PM
Fairman Jeff	VP, Research	Dec 09	Option Exercise	1.79	131	234	6,291	Dec 13 05:20 PM
Fairman Jeff	VP, Research	Dec 09	Sale	22.50	131	2,948	6,160	Dec 13 05:20 PM
PICKERING GRANT	Chief Executive Officer	Nov 19	Option Exercise	1.79	15,000	26,850	595,254	Nov 23 05:10 PM
PICKERING GRANT	Chief Executive Officer	Nov 19	Sale	23.45	15,000	351,710	580,254	Nov 23 05:10 PM
GUGGENHIME ANDREW	President and CFO	Nov 18	Option Exercise	5.35	3,100	16,585	6,225	Nov 22 04:58 PM
GUGGENHIME ANDREW	President and CFO	Nov 18	Sale	24.53	3,100	76,030	3,125	Nov 22 04:58 PM
Sauer Paul	SVP Process Dev, Manufacturing	Nov 01	Sale	25.00	3,000	75,000	33,125	Nov 03 05:55 PM
Fairman Jeff	VP, Research	Oct 26	Option Exercise	1.79	4,750	8,502	9,894	Oct 28 06:00 PM
Fairman Jeff	VP, Research	Oct 26	Sale	22.69	4,750	107,778	5,144	Oct 28 06:00 PM
PICKERING GRANT	Chief Executive Officer	Oct 20	Option Exercise	1.79	15,000	26,850	595,254	Oct 22 04:46 PM
PICKERING GRANT	Chief Executive Officer	Oct 20	Sale	22.58	15,000	338,756	580,254	Oct 22 04:46 PM
Fairman Jeff	VP, Research	Sep 27	Option Exercise	1.79	4,750	8,502	9,894	Sep 29 07:52 PM
Fairman Jeff	VP, Research	Sep 27	Sale	26.17	4,750	124,303	5,144	Sep 29 07:52 PM
PICKERING GRANT	Chief Executive Officer	Sep 22	Option Exercise	1.79	4,193	7,505	584,447	Sep 23 05:40 PM
Sauer Paul	SVP Process Dev, Manufacturing	Sep 22	Sale	25.20	5,307	133,724	36,125	Sep 24 05:04 PM
PICKERING GRANT	Chief Executive Officer	Sep 22	Sale	25.19	4,193	105,636	580,254	Sep 23 05:40 PM
PICKERING GRANT	Chief Executive Officer	Sep 21	Option Exercise	1.79	10,807	19,345	591,061	Sep 23 05:40 PM
PICKERING GRANT	Chief Executive Officer	Sep 21	Sale	25.22	10,807	272,590	580,254	Sep 23 05:40 PM
Fairman Jeff	VP, Research	Aug 26	Option Exercise	1.79	4,750	8,502	9,894	Aug 30 06:06 PM
Fairman Jeff	VP, Research	Aug 26	Sale	25.38	4,750	120,543	5,144	Aug 30 06:06 PM
PICKERING GRANT	Chief Executive Officer	Aug 23	Option Exercise	1.79	13,669	24,468	593,923	Aug 25 06:11 PM
PICKERING GRANT	Chief Executive Officer	Aug 23	Sale	22.73	13,669	310,722	580,254	Aug 25 06:11 PM
PICKERING GRANT	Chief Executive Officer	Aug 19	Option Exercise	1.79	1,331	2,382	581,585	Aug 20 04:19 PM
PICKERING GRANT	Chief Executive Officer	Aug 19	Sale	22.40	1,331	29,810	580,254	Aug 20 04:19 PM
Wright-Mitchell Jane	General Counsel	Aug 16	Option Exercise	2.03	2,500	5,075	5,625	Aug 18 06:02 PM
Wright-Mitchell Jane	General Counsel	Aug 16	Sale	26.00	2,500	65,000	3,125	Aug 18 06:02 PM
Wright-Mitchell Jane	General Counsel	Aug 12	Option Exercise	2.03	10,000	20,300	13,125	Aug 16 04:31 PM
Wright-Mitchell Jane	General Counsel	Aug 12	Sale	26.00	10,000	260,000	3,125	Aug 16 04:31 PM
Fairman Jeff	VP, Research	Jul 26	Option Exercise	1.79	4,750	8,502	9,894	Jul 28 04:32 PM
Fairman Jeff	VP, Research	Jul 26	Sale	22.70	4,750	107,825	5,144	Jul 28 04:32 PM
PICKERING GRANT	Chief Executive Officer	Jul 20	Option Exercise	1.79	15,000	26,850	595,254	Jul 22 04:58 PM
PICKERING GRANT	Chief Executive Officer	Jul 20	Sale	22.85	15,000	342,686	580,254	Jul 22 04:58 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience